$ZLAB

Lis William sold $127K of ZLAB

Lis William sold 7,040 shares of Zai Lab Ltd (ZLAB) at $18.09 ($0.13M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lis William
Published Jun 24, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ZLAB
Neutral
high confidence
Mentioned
$ZLAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

The disclosed sale can marginally influence short-term sentiment, but the 10b5-1 pre-arrangement generally lowers the informational content for fundamental repricing.

02

Market read

Traders may monitor for follow-on insider activity, but this specific transaction is unlikely to drive a material repricing.

03

What to watch

The filing does not disclose intent beyond the plan; without additional context (e.g., other insider buys/sales around the same window), the signal is limited.

Relevance 3/10Novelty 5/10Timing: after-hours/filing date (2026-06-24) for a 2026-06-22 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Zai Lab Ltd, reporting a director’s open-market sale.

Company-level read

Ticker impact

$ZLABNeutralHigh confidence
Context

SEC Form 4 shows director Lis William sold 7,040 Zai Lab shares on 2026-06-22 under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale by a director with an explicitly pre-arranged 10b5-1 plan, which typically reduces signaling risk versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so traders may ignore it.

Key entities

  • Zai Lab Ltd

    Company whose shares were sold by a director under a 10b5-1 plan.

  • Lis William

    Director who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ZLABMedAI 8/10

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

$ZLABHighAI 9/10

Why is Zai Lab stock surging today?

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

$ZLABMedAI 8/10

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab (ZLAB) reported positive Phase 1b trial results for zocilurtatug pelitecan (zoci) plus atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). The combination achieved an 81.8% response rate and 81.9% 6-month progression-free survival rate. The therapy was well-tolerated, with Grade >3 adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

$ZLABMedAI 9/10

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

$ZLABHighAI 9/10

Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.